Harvard Bioscience, Inc. provided revenue guidance for the year 2022. The company expects year-over-year revenue growth in the range of 8% to 13% versus last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | +0.68% | -1.34% | -45.05% |
May. 07 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.05% | 128M | |
+7.23% | 217B | |
+11.31% | 191B | |
+28.94% | 154B | |
+32.00% | 112B | |
-0.46% | 62.84B | |
+16.09% | 53.34B | |
+0.94% | 48.83B | |
-2.97% | 39.36B | |
+1.23% | 35.73B |
- Stock Market
- Equities
- HBIO Stock
- News Harvard Bioscience, Inc.
- Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2022